Jamie Pearson of New Holland Group joins Bryan Fields on The Dime to discuss European cannabis expansion, EU GMP standards, medical cannabis supply chains, and why operational discipline and market fit matter before entering international markets.
Global expansion is often pitched as an opportunity. For an undisciplined cannabis company, it is an expensive way to expose every weakness at once.
International markets reward specific operating capabilities, not ambition alone. Pharmaceutical standards, reliable supply, disciplined data use, and local market fit determine whether an operator can cross borders without compounding its problems.
This week we sit down with Jamie Pearson
On The Dime, host Bryan Fields speaks with Jamie L. Pearson, President and Founder of New Holland Group, about European cannabis expansion, medical cannabis supply chains, and building operations that can succeed across borders.
00:00 Regulation is breaking the data layer
02:49 Finding trend data upstream
06:24 What EU GMP actually demands
10:19 Why compliant facilities become strategic assets
16:13 Canada-Europe regulatory harmony
19:20 Europe is medical first
25:28 First-mover advantage vs. disciplined execution
27:59 Medical supply rewards repeatability
30:48 Weak operations do not travel
32:24 Switzerland, Slovenia, and Portugal
35:54 Brazil and partner requirements
37:07 Practice expansion before global scale
40:08 The hidden U.S. hemp market
43:29 Turning customers into political force
47:10 Directness as respect
Germany Is the Engine: What BAT Knows That Cannabis Doesn't ft. James Yamanaka — continue exploring Germany's cannabis market and operational discipline.
Follow The Dime for more conversations on cannabis business, operations, and international markets. Share this episode with an operator considering expansion.